Sleep Med Psychophysiol.  1997 Dec;4(2):181-190.

Comparison of Effects of Zolpidem, Triazolam, and Placebo on the Insomnia of Schizophrenic Inpatients

• Park SY
• Sohn JW

Abstract

Zolpidem is a relatively new, short-acting, rapid onset, and nonbenzodiazepine hypnotics. Zolpidem selectively binds to the central benzodiazepine 1 (BZI) receptor subtype. The present study was designed to compare the hypnotic effects of zolidem (10mg), triazolam (0.25mg), and placebo in 22 schizophrenic inpatients. Zopidem, triazoam, and placebo were administered orally in a randomized, double-blind design. Compared with placebo, zolpidem and triazolam significantly decreased sleep latency (p<0.05), increased total sleep time(p<0.05), and increased improvement of satisfaction of sleep(p<0.05). Zolpidem decreased the number of awakenings significantly in comparison with placebo(p<0.05),but trialzolam did not. In addition, both drugs were well tolerated and did not produce severe side effects. These results suggest that zolpidem is effective for transient insomnia of schizophrenic inpatients and zolpidem is superior to triazolam in hypnotic effect.

Keyword

Insomnia; Schizophrenia; Zolpidem Triazolam

MeSH Terms

Benzodiazepines
Humans
Hypnotics and Sedatives
Inpatients*
Schizophrenia
Sleep Initiation and Maintenance Disorders*
Triazolam*
Benzodiazepines
Hypnotics and Sedatives
Triazolam